Why patients switch
The most common reasons patients switch GLP-1 telehealth providers, in our reviewer experience: (1) the dose-step pricing model at the original provider raised the maintenance-phase cost meaningfully above the introductory quote; (2) the original provider's clinical relationship is thin (no follow-up, hard to reach a clinician); (3) pharmacy disclosure turned out to be weaker than implied at signup; (4) the original provider sunset its compounded program, leaving the patient to find a continuation pathway.
Get your medical records first
Before switching, obtain a copy of your medical records from the current program. This typically includes the clinical intake notes, prescribed regimen, lab results, and any documented adverse events. Most programs will provide this on request under HIPAA at no charge.
Having documentation of the dose you're currently on, the pharmacy partner that's been dispensing, and the date of your last dose lets the new program continue your regimen without restarting the titration ladder — assuming clinical appropriateness.
Plan the timing of the switch
GLP-1s are dosed weekly. The cleanest switch timing is so that your new program's first shipment arrives before your last vial from the prior program runs out. Build in a 1–2 week buffer for intake delays.
If you must pause therapy briefly, a 1–2 week gap is usually tolerated — though some patients report a brief return of appetite. A gap of more than 4 weeks typically warrants stepping back one dose level when resuming, due to loss of GI tolerance.
What to ask the new provider during intake
Three questions that surface most of what matters: (1) Can you continue me on my current dose, or do I need to step back? (2) Which named pharmacy will be dispensing, and is it 503A or 503B? (3) What's the price at the dose I expect to maintain — not just the introductory dose?
A program that answers all three clearly during intake is operating at a transparency level meaningfully above the industry median.